Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

Sarah E Ivory, David K Packham, Anne Therese Reutens, Rory St John Wolfe, Richard Rohde, Julia B Lewis, Robert Charles Atkins

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)


Aim Proteinuria and estimated glomerular filtration rate (eGFR) predict progression of renal impairment in type 2 diabetic nephropathy (DN) but are they still predictive when these patients are treated with angiotensin receptor blockers (ARB)? We investigated whether residual (after =3 months of ARB treatment) urinary protein/creatinine ratio (rPCR) or urinary albumin/creatinine ratio (rACR) and residual eGFR (reGFR), predict subsequent progression. Methods One thousand, two hundred and forty-five patients with type 2 DN from two international multi-center studies were analysed. Cross classification of rPCR, rACR with reGFR (rPCR:
Original languageEnglish
Pages (from-to)516 - 524
Number of pages9
Issue number7
Publication statusPublished - 2013

Cite this